e-learning
resources
ERJ
2002
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations?
Willaert W., Daenen M., Bomans P., Verleden G., Decramer M.
Source:
Eur Respir J 2002; 19: 928-935
Journal Issue:
May
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Willaert W., Daenen M., Bomans P., Verleden G., Decramer M.. What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations?. Eur Respir J 2002; 19: 928-935
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
The role of nebulised budesonide in the treatment of exacerbations of COPD
Source: Eur Respir J 2007; 29: 660-667
Year: 2007
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 21: 74-81
Year: 2003
Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2001; 18: Suppl. 33, 146s
Year: 2001
Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter?
Source: Eur Respir J 2003; 21: 260-266
Year: 2003
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 19: 217-224
Year: 2002
Modern treatment of chronic obstructive pulmonary disease
Source: Eur Respir J 2001; 18: 60S-66S
Year: 2001
Osteoporosis risk assessment in elderly male patients with COPD who use inhaled corticosteroids
Source: Annual Congress 2006 - COPD therapy
Year: 2006
Mechanism by which inhaled bronchodilators prevent exacerbations in chronic obstructive pulmonary disease
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013
The role of bronchodilator treatment in the prevention of exacerbations of COPD
Source: Eur Respir J 2012; 40: 1545-1554
Year: 2012
The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use
Source: Eur Respir J 2001; 18: Suppl. 33, 515s
Year: 2001
Roflumilast with long-acting ?2-agonists for COPD: influence of exacerbation history
Source: Eur Respir J 2011; 38: 553-560
Year: 2011
Inhaled maintenance therapy and risk of first or subsequent emergency department visit/hospitalization in patients with COPD
Source: Annual Congress 2006 - COPD therapy
Year: 2006
Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use
Source: Eur Respir J 2001; 18: Suppl. 33, 514s
Year: 2001
Inhaled corticosteroids and hospitalisation due to exacerbation of COPD
Source: Eur Respir J 2003; 22: 286-289
Year: 2003
Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease
Source: Eur Respir J 2001; 18: 903-908
Year: 2001
Medical personnel‘s ability to use pressurized metered dose inhaler (pMDI) in India
Source: Annual Congress 2006 - The challenges of managing asthma in primary care
Year: 2006
Audit of inhaled corticosteroid prescription in chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2010 - COPD: management
Year: 2010
Where current pharmacological therapies fall short in COPD: symptom control is not enough
Source: Eur Respir Rev 2007; 16: 98-104
Year: 2007
A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations
Source: Eur Respir J 2013; 41: 12-17
Year: 2013
Inhaled corticosteroids and the risk of a first exacerbation in COPD patients
Source: Eur Respir J 2004; 23: 692-697
Year: 2004
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept